- Home
- CRTO vs AVTX Comparison
CRTO vs AVTX Comparison
Compare CRTO & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRTO | AVTX |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 982.5M |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CRTO | AVTX |
|---|---|---|
| Price | $17.24 | $20.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $34.00 | ★ $40.57 |
| AVG Volume (30 Days) | 467.3K | ★ 722.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.95 | ★ 72.07 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $2,296,692,000.00 | $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | $45.86 | ★ N/A |
| Revenue Growth | 27.65 | ★ 2312.27 |
| 52 Week Low | $15.58 | $8.65 |
| 52 Week High | $25.29 | $24.27 |
Technical Indicators
Market Signals| Indicator | CRTO | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.33 | 56.87 |
| Support Level | $16.36 | $17.40 |
| Resistance Level | $19.55 | $20.60 |
| Average True Range (ATR) | 0.74 | 0.95 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 24.55 | 75.17 |
Price Performance
Historical ComparisonAbout CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.